Screening Compounds
The world-renowned BIONET screening catalogue currently contains just under 54,000 compounds, comprising 41,300+ BIONET Screening Compounds and 12,500+ BIONET Fragment Libraries compounds.
These compounds have proven activity across sectors in pharma, biotech and agro industries (please see the BIONET fact sheet for more information).
Over 90% of these compounds are unique to BIONET. Further enhancement is provided with the addition of selected compounds from trusted external suppliers.
BIONET Pre-Plated Diversity Sets
BIONET diversity sets offer a representative and cost-effective 'taster' of the entire catalogue, to enable targeted follow-up purchase of specific BIONET compounds most closely matching a client's particular areas of interest.
Click here to find out more.
NEW! BIONET CNS Leadlike Screening Library
A subset of 1,962 Leadlike compounds filtered to ensure physiochemical properties suitable for Central Nervous System applications.
Studies have suggested that the following rules can provide guidance when choosing compounds intended to enter the brain:
Rule 1: If N + O in a compound is ≤ 5 then the compound has a high chance of entering the CNS [1].
Rule 2: If CLogP – (N+O)>0 then LogBB is likely to be positive [1].
Rule 3: For good brain permeation the polar surface area should have a lower limit of 60-70Å2 [2].
Rule 4: Molecular weight should be kept below 450 to facilitate CNS permeation [3].
Rule 5: CNS drugs tend to be more rigid compared to non CNS drugs [4].
BIONET have revised these rules and produced a stricture set of physiochemical filters to promote leadlike properties:
BIONET Screening Fragments
The BIONET Fragments catalogue currently contains over 12,500 screening compounds, comprising;
- the BIONET 'Rule of Three' ('Ro3') library of over 7,800 compounds
- the BIONET Extended Fragment Library of just under 4,400 compounds
Click here to find out more.
BIONET Chiral Cyclic Fragment Library:
This library contains 19 compounds enabling drug discovery through chirality.
Rapid, cost-effective exploration of 3D chemical space is possible using these unique chiral compounds, bioanalytically prepared for unbeatable chemical and enantiomeric purity.
Click here for more information.
BIONET Anti-Malarial Agents - click here for more details!
BIONET Active Compounds for CNS Research - click here for more details!
BIONET Active Compounds for Cancer Research - click here for more details!
BIONET Synthetic Mimics of Pyrabactin - click here for more details!
Stock Levels – Updated January 2012:
- 90% of BIONET Screening Compounds are in stock ≥20mg
Re-supply for follow up work - Updated January 2012:
- 87% of BIONET Screening Compounds in stock ≥ 100mg
- 73% of BIONET Screening Compounds in stock ≥ 500mg
- 58% of BIONET Screening Compounds in stock ≥ 1g
Quality
The standard minimum purity for BIONET Screening compounds is >90%. Every compound is quality-assured by the in-house Analytical Department.
Flexibility
BIONET compounds can be ordered directly from Key Organics by telephone, email, e-trading, and through its worldwide network of agents.
Service
Key Organics' dedicated Customer Relations Department is available to answer any queries that you may have and will handle your order efficiently. 24-hour delivery is available for small orders placed before 10am UK time.
Database Download
To download all the latest Bionet Fragment databases please click here.
Also to receive our updates please register here.
[1] Norinder, U. and Haeberlein, M. (2002) Computational approaches to the prediction of blood brain distribution. Adv. Drug Deliv. Rev. 54, 291-313
[2] Kelder, J. Et al. (1999) Polar molecular surface area as a dominating determinant for oral absorption and brain permeation of drugs. Pharm. Res. 16, 1514-1519
[3] Van de Waterbeemd, H. et al. (1998) Estimation of blood-brain barrier crossing of drugs using molecular size and shape and H-bonding descriptors. J, Drug Target. 6, 151-165
[4] Doan, K.M. et al. (2002) Passive permeability and P-glycoprotein mediated efflux differentiate central nervous system (CNS) and non CNS marketed drugs. J. Pharmacol. Exp. Ther. 303, 1029-1037